Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Clotblog with Dr Samuel Goldhaber
View all posts »FDA advisory exonerates dabigatran (Pradaxa) on serious bleeding relative to warfarin
Nov 30, 2012 00:00 EST-
0Comments
-
Read later
The recent FDA drug safety communication exonerates dabigatran by its finding in a postmarket review that serious bleeding with new use of the drug does not appear to be higher than serious bleeding associated with new use of warfarin.
See:
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
